---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-21-313521"
form_type: "8-K"
ticker: "BVS"
cik: "0001665988"
company_name: "Bioventus Inc."
filed_at: "2021-10-29T23:59:59+00:00"
generated_at: "2026-06-28T16:15:38.061044+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bioventus completes Misonix acquisition; $183M cash plus 18.3M shares issued

## Summary
- Misonix shareholders received $28 cash or 1.6839 BVS shares per share; total consideration $182.99M cash and 18.34M BVS shares.
- New $262M term loan added to finance the merger; $80M of existing Bioventus term loan prepaid.
- Stavros Vizirgiankis and Patrick Beyer appointed to Bioventus board effective closing.
- Combined company targets $15B addressable market; expects double-digit revenue growth.
- Misonix becomes wholly owned subsidiary of Bioventus; operations continue.

## SEC filing metadata
- accession: 0001193125-21-313521
- form_type: 8-K
- ticker: BVS
- cik: 0001665988
- company_name: Bioventus Inc.
- filed_at: 2021-10-29T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.01, 2.03, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1665988/000119312521313521/0001193125-21-313521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1665988/000119312521313521/d248592d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-21-313521
- JSON: https://secwatch.observer/filing/0001193125-21-313521.json
- Plain text: https://secwatch.observer/filing/0001193125-21-313521.txt

## Key facts
- Executive change
  Patrick J. Beyer was appointed as Director at Bioventus Inc..
  - Action: appointed
  - Role: Director
  source text: The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312521313521/0001193125-21-313521-index.htm
- Executive change
  Stavros G. Vizirgiankis was appointed as Director at Bioventus Inc..
  - Action: appointed
  - Role: Director
  source text: The Board of Directors (the “Board”) of the Company appointed Stavros G. Vizirgiankis and Patrick J. Beyer to the Board, conditioned and effective upon the First Effective Time, in accordance with the terms of the Merger Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1665988/000119312521313521/0001193125-21-313521-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.